ROTH Capital Partners, a full service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Inaugural Healthcare Opportunities Conference in New York City on Oct. 6, 2022. The conference will feature approximately 25 public healthcare companies that have been selected by ROTH’s research analysts and provide C-level executives the opportunity to closely interact with pre-qualified institutional investors and healthcare industry professionals. The event will have a multiple sub-sector focus with participating companies operating in biotechnology, pharmaceuticals, medical technologies, oncology and mental health therapeutics. “Most healthcare conferences are skewed toward companies whose market capitalizations are quite large,” said Tony Butler, Ph.D., managing director, senior research analyst and head of biotechnology research. “Investments may be crowded. Our conference offers opportunities for investors to possibly generate higher alpha within their portfolios.”
To view the full press release, visit https://ibn.fm/sQiI3
About ROTH Capital Partners LLC
ROTH Capital Partners is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, California, ROTH is privately held and owned by its employees and maintains offices throughout the U.S. For more information on ROTH, please visit www.ROTH.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio…
Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. A clinical-stage…
VERAXA Biotech (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its novel BiTAC(TM)-ADC technology platform, which…
Earth Science Tech (OTC: ETST) reported financial results for the fiscal year ended March 31, 2026,…
Oncotelic Therapeutics (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices manufacturing…
Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on personalized, data-driven cardiovascular care powered by artificial intelligence, epigenetics…